This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eli Lilly, Verve Therapeutics to file US antitrust paperwork today

By Flavia Fortes ( June 25, 2025, 11:16 GMT | Insight) -- Eli Lilly and Verve Therapeutics expect to file the notification of their $1 billion deal with US antitrust authorities today, Verve said in a filing with the US Securities and Exchange Commission. The waiting period under the Hart-Scott-Rodino Act is expected to expire on July 25, unless the transaction is granted early termination, the parties refile paperwork, or officials issue a request for additional information. Eli Lilly and Verve Therapeutics expect to file the notification of their $1 billion deal with US antitrust authorities today, Verve said in a filing with the US Securities and Exchange Commission....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login